DUE: September 7, 2026 The National Cancer Institute invites applications for projects to expand, improve, or transform the utility of mammalian cancer and tumor models for translational research.
DUE: August 31, 2028 Funding opportunity to develop strategies and interventions to improve diagnostic safety in the heterogenous ambulatory care environment.
DUE: September 7, 2026 Seeking applications for identification of small molecules that function to elucidate the biology of disease as chemical probes or function as agonists or antagonists of disease target(s) for therapy or immunotherapy.
DUE: January 7, 2027 Funding available to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk
NTA is operated by the 501c(3) non-profit Advanced Technology International (ATI). National Technology Alliance (NTA) © 2024 - All rights reserved.